Wegovy vs. Mounjaro: The Verdict, the Price, and the FDA Catch

Is Mounjaro actually stronger than Wegovy for weight loss?

The clearest answer came out of SURMOUNT-5, published in May 2025 in the New England Journal of Medicine — the first trial to put both molecules through the same protocol instead of comparing separate studies run years apart. Adults with obesity, none of them living with diabetes, were randomized to the maximum tolerated dose of tirzepatide or semaglutide and followed for 72 weeks. Tirzepatide, the active ingredient in Mounjaro, produced a mean weight loss of about 20% of starting body weight. Semaglutide, Wegovy's active ingredient, produced about 14%. A larger share of the tirzepatide group also crossed every major weight-loss threshold researchers track, from 10% up through 25%, and their blood pressure, triglycerides, and blood sugar markers moved further too.

One detail dates that headline, and it matters if you're weighing the two today. SURMOUNT-5 titrated semaglutide to 2.4mg, which was Wegovy's top approved dose while the trial was running. That changed in March 2026, when the FDA approved Wegovy HD — a 7.2mg strength that produced about 20.7% average weight loss over 72 weeks in its own trial, landing much closer to what tirzepatide managed in SURMOUNT-5.

That narrows the gap on paper without settling it. The two figures come from separate trials with different participants, and no study has yet run tirzepatide against semaglutide at 7.2mg, which is the only comparison that would answer the question cleanly. The higher dose is also a step up rather than a starting point: it's approved for people who have already tolerated 2.4mg for at least a month and still have weight to lose, and gastrointestinal side effects turned up more often at 7.2mg than at 2.4mg.

Those numbers are trial averages, not a promise for any one person — dose, adherence, diet, and individual physiology all move the result. Tirzepatide still holds the only direct head-to-head win between the two molecules; what Wegovy's newer dose calls into question is the size of that lead, not its existence.

Wegovy and Mounjaro aren't approved for the same thing — does that matter for you?

This is probably the single most decision-changing fact in the whole comparison, and it's easy to miss because both drugs get talked about in the same weight-loss conversations online. Wegovy was FDA-approved in 2021 specifically for chronic weight management, and picked up a second indication in March 2024 for reducing cardiovascular risk in adults with established heart disease and overweight or obesity, based on the SELECT trial. In December 2025, Wegovy also gained FDA approval as a once-daily oral tablet — the first oral GLP-1 approved for weight management — with a US pharmacy launch that followed in early 2026, alongside the original weekly injection; the pill-versus-injection decision itself is its own separate question covered on Wegovy pills and patches.

Mounjaro carries none of that. It was approved in May 2022 for one purpose only: improving blood sugar control in adults with type 2 diabetes. It has never picked up a weight-management indication — that belongs to its sister brand, Zepbound, which shares the same active ingredient, tirzepatide, at the same top doses. A prescriber can still write a Mounjaro prescription off-label for weight loss, and that's legal and fairly common in obesity medicine. But everything downstream of that prescription changes: insurance pays by indication, not by molecule, so a plan that covers Mounjaro for a documented diabetes diagnosis can and often does deny the identical drug when the only diagnosis on the chart is obesity.

What's the real difference between semaglutide and tirzepatide?

Semaglutide, Wegovy's molecule, acts on a single hormone receptor, GLP-1, slowing digestion and quieting appetite signals in the brain. Tirzepatide, Mounjaro's molecule, does that same GLP-1 work but adds a second receptor, GIP, that appears to compound the effect on appetite and blood sugar — sometimes described as a dual-action or 'twincretin' mechanism. That second receptor is the leading explanation for the SURMOUNT-5 gap above, though exactly how much of the difference comes from the extra receptor versus the specific doses tested is still being studied. For the fuller mechanism-level breakdown, semaglutide vs. tirzepatide goes deeper than this page needs to; here the focus stays on what the molecule difference means for the Wegovy-versus-Mounjaro decision specifically.

Wegovy vs. Mounjaro: which costs less — self-pay, insured, or compounded?

Wegovy wins on price at nearly every brand self-pay and retail tier, and its on-label status gives it an insured pathway Mounjaro can't match without a diabetes diagnosis. Compounded versions of both molecules undercut every brand pathway on price, if you're comfortable with what that trade-off means. The table above lines up the comparable numbers; the sections below walk through what's actually behind each one.

Compounded tirzepatide vs. compounded semaglutide

The cheapest verified options on this whole comparison come from two different telehealth providers. Curex holds the lowest all-in price for compounded tirzepatide, around $199 a month with medication, consult, and shipping bundled and no separate membership fee. Fridays holds the lowest verified price for compounded semaglutide, running $150 to $249 a month depending on plan length. Neither is FDA-approved Mounjaro or Wegovy — both are dispensed under a narrower 503A individual-patient compounding pathway now that each molecule's FDA shortage designation has been resolved, which means a documented clinical reason beyond cost savings is technically what the pathway requires.

Without insurance: NovoCare's ladder vs. Mounjaro's missing one

Novo Nordisk runs its own cash-pay pharmacy for Wegovy through NovoCare: $199 a month for the first two fills at the starter dose, an offer running through the end of 2026, then $349 a month through the standard maintenance doses or $399 for the highest injectable strength. The oral tablet has its own ladder, starting around $149 a month.

Eli Lilly has no equivalent self-pay vial program for the Mounjaro brand itself — a genuinely uninsured patient is paying close to list price, with GoodRx trimming only a modest amount off that. If brand-name tirzepatide at a real self-pay price is the goal, that program does exist; it's just sold as Zepbound, not Mounjaro, through LillyDirect at $299 to $449 a month depending on dose, since Zepbound carries the obesity indication that unlocks it.

With insurance and the manufacturer savings card

This is where the indication gap shows up most clearly. Wegovy's savings card asks only that your commercial plan cover Wegovy — since weight management is the approved use, a weight-loss diagnosis is exactly what the card expects to see, and it can bring your cost to around $25 a month. Mounjaro's savings card structure looks identical on the surface, $25 a month at its best tier, but the fine print requires both commercial insurance that covers Mounjaro and a prescription matching its type-2-diabetes label specifically — a chart that reads 'weight loss' rather than 'type 2 diabetes' disqualifies you, even with insurance in hand. If your plan has commercial coverage but doesn't cover Mounjaro at all, the card still helps at $499 a month, a real discount off list but nowhere near Wegovy's insured rate.

• Compounded, cheapest verified pathway, annualized: roughly $1,800–$2,988/year for semaglutide (Fridays), about $2,388/year for tirzepatide (Curex) — the lowest cost tier on this comparison for either molecule.
• Wegovy, NovoCare self-pay standard tier, annualized: roughly $4,188/year at $349/mo.
• Mounjaro, retail with no program, annualized: roughly $12,960–$13,344/year at $1,080–$1,112/mo — the real number for an uninsured patient, since there's no brand self-pay ladder to fall back on.
• Either drug, insured with a qualifying savings card: roughly $300/year at $25/mo — but only Wegovy reaches that tier off a weight-loss diagnosis alone.
• Mounjaro, insured but not covered, savings card tier: roughly $5,988/year at $499/mo — still thousands cheaper than retail, but well above Wegovy's insured rate.

Does insurance cover Wegovy or Mounjaro more easily for weight loss?

For weight loss specifically, Wegovy has the real structural advantage, because coverage rules are built around the label. Most commercial plans that include an obesity or weight-management benefit at all will consider Wegovy, typically after prior authorization documenting BMI, a qualifying comorbidity, and often a prior attempt at lifestyle treatment. Mounjaro, prescribed for the same reason, usually gets denied outright, because the chart doesn't match the drug's approved use — insurers pay by indication, and 'obesity' isn't Mounjaro's indication no matter how effective the molecule is. Medicare is even more absolute: federal law bars Part D from covering any drug prescribed solely for weight loss, so Mounjaro used off-label for that purpose gets zero Medicare coverage regardless of how the appeal is worded.

None of this means Mounjaro is uninsurable — if you carry a genuine, documented type-2-diabetes diagnosis, coverage for it is common, just gated behind the same prior-authorization process as most GLP-1 prescriptions. The practical takeaway if weight management is your actual goal: Wegovy's on-label status gives your prescriber a real coverage argument to make; a Mounjaro prescription written for weight loss alone generally doesn't have one.

Side effects — is one easier to tolerate?

Both drugs cause the same family of gastrointestinal side effects, for the same underlying reason — slowing digestion is the mechanism, not an unrelated side issue of it. Nausea, vomiting, diarrhea, and constipation are the most commonly reported problems with both, usually clustering hardest in the weeks right after a dose increase before easing.

In SURMOUNT-5, gastrointestinal side effects severe enough to stop treatment happened more often on semaglutide than tirzepatide — about 5.6% versus 2.7% of participants. Some separate trial and real-world data point to a difference in which symptom shows up more, semaglutide skewing slightly toward nausea and constipation, tirzepatide slightly toward looser stools, though neither pattern is universal. Plenty of women tolerate one drug better than the other for reasons that don't show up cleanly in a trial average.

Which one is right for you? Verdict by profile

• Weight loss is your actual goal and you want insurance to have a real shot at covering it: Wegovy. It's the one of the two with the on-label indication, which is what most obesity-benefit formularies and savings cards are actually built around.
• You want the strongest average result and cost is secondary: Mounjaro's molecule holds the only head-to-head win, from SURMOUNT-5 — though Wegovy's 7.2mg dose has since narrowed that margin, so the edge is smaller than the trial headline implies.
• You're paying cash and budget is the deciding factor: compounded pricing beats every brand option for either molecule, and among the brands, Wegovy is cheaper at nearly every self-pay and retail tier since there's no equivalent Mounjaro-branded self-pay program to close that gap.
• You already have a documented type-2-diabetes diagnosis: let coverage decide — a plan that covers Mounjaro for T2D at $25/mo rarely loses to fighting for an off-label alternative.
• You've struggled with nausea on a GLP-1 before: the SURMOUNT-5 discontinuation data gives tirzepatide (Mounjaro's molecule) a slight edge on tolerability, though this varies person to person.
• Needles are a hard no: Wegovy's oral tablet is the only pill-form option between the two — see Wegovy pills and patches for how that pathway compares on its own terms.

Can you switch between Wegovy and Mounjaro?

Yes, and clinicians make this kind of switch routinely — most often triggered by a plateau, hard-to-tolerate side effects, or a formulary change that suddenly makes one drug cheaper than the other. There's no FDA-established dose equivalency between semaglutide and tirzepatide, so it isn't a matter of converting your current dose to a matching one on the other drug. In practice, most prescribers restart the new medication at its lowest introductory level rather than matching where you left off, timing the change around each drug's weekly dosing schedule. How that transition gets managed is worth working through directly with whoever is prescribing, since it varies by provider and by how you responded to the first drug.

Wegovy vs. Mounjaro for perimenopause and menopause weight gain

The weight shift that shows up in perimenopause has a specific hormonal driver: falling estrogen worsens insulin resistance and pushes fat storage toward the abdomen, on top of whatever else is going on in a woman's life at 40-plus. Both molecules act on pathways relevant to that shift — improving insulin sensitivity and quieting appetite signaling — which is part of why obesity-medicine physicians increasingly view GLP-1 drugs as reasonably well matched to the perimenopausal metabolic picture generally.

No trial has isolated a perimenopausal or postmenopausal subgroup for either SURMOUNT-5 or either drug's approval studies, so there's no menopause-specific verdict to report between Wegovy and Mounjaro specifically. For most women in this stage without a type-2-diabetes diagnosis, the more useful real-world question usually isn't Wegovy versus Mounjaro at all — it's whether an on-label weight-management option fits their situation and budget better than a diabetes-branded drug used off-label, which is exactly the asymmetry this whole comparison comes back to.